1. Home
  2. FOA vs ALLO Comparison

FOA vs ALLO Comparison

Compare FOA & ALLO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • FOA
  • ALLO
  • Stock Information
  • Founded
  • FOA 2013
  • ALLO 2017
  • Country
  • FOA United States
  • ALLO United States
  • Employees
  • FOA N/A
  • ALLO N/A
  • Industry
  • FOA Finance Companies
  • ALLO Biotechnology: Biological Products (No Diagnostic Substances)
  • Sector
  • FOA Finance
  • ALLO Health Care
  • Exchange
  • FOA Nasdaq
  • ALLO Nasdaq
  • Market Cap
  • FOA 272.8M
  • ALLO 252.9M
  • IPO Year
  • FOA N/A
  • ALLO 2018
  • Fundamental
  • Price
  • FOA $22.71
  • ALLO $1.26
  • Analyst Decision
  • FOA Buy
  • ALLO Buy
  • Analyst Count
  • FOA 2
  • ALLO 12
  • Target Price
  • FOA $27.50
  • ALLO $8.80
  • AVG Volume (30 Days)
  • FOA 122.0K
  • ALLO 3.0M
  • Earning Date
  • FOA 11-04-2025
  • ALLO 11-13-2025
  • Dividend Yield
  • FOA N/A
  • ALLO N/A
  • EPS Growth
  • FOA N/A
  • ALLO N/A
  • EPS
  • FOA 7.10
  • ALLO N/A
  • Revenue
  • FOA $527,520,999.00
  • ALLO N/A
  • Revenue This Year
  • FOA $21.21
  • ALLO N/A
  • Revenue Next Year
  • FOA $10.95
  • ALLO $100.00
  • P/E Ratio
  • FOA $3.20
  • ALLO N/A
  • Revenue Growth
  • FOA 46.94
  • ALLO N/A
  • 52 Week Low
  • FOA $11.33
  • ALLO $0.86
  • 52 Week High
  • FOA $32.40
  • ALLO $3.78
  • Technical
  • Relative Strength Index (RSI)
  • FOA 48.19
  • ALLO 51.00
  • Support Level
  • FOA $22.38
  • ALLO $1.21
  • Resistance Level
  • FOA $23.21
  • ALLO $1.33
  • Average True Range (ATR)
  • FOA 0.83
  • ALLO 0.09
  • MACD
  • FOA 0.22
  • ALLO -0.01
  • Stochastic Oscillator
  • FOA 69.15
  • ALLO 20.59

About FOA Finance of America Companies Inc.

Finance of America Companies Inc is a financial services holding company that, through its operating subsidiaries, is a modern retirement solutions platform that provides customers with access to a range of retirement offerings centered on the home. In addition, FoA offers capital markets and portfolio management capabilities to optimize the distribution of its originated loans to investors. It operates through two segments: Retirement Solutions and Portfolio Management. It generates the majority of its revenue from Retirement Solutions.

About ALLO Allogene Therapeutics Inc.

Allogene Therapeutics Inc is a clinical-stage biotech firm specializing in immuno-oncology, focusing on the development of genetically engineered allogeneic T-cell products for cancer and autoimmune diseases. Their pipeline includes off-the-shelf T-cell candidates designed to target cancer cells or autoreactive cells in autoimmune disorders. Notably, their allogeneic approach, derived from healthy donors, allows for broader patient eligibility and scalability. With a vision to redefine CAR T therapy, the company concentrates on core programs targeting lymphoma, leukemia, autoimmune diseases, and solid tumors. Revenue, generated from collaborations and licensing agreements, supports their research and development efforts.

Share on Social Networks: